Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124920223 | 12492022 | 3 | F | 20160826 | 20160623 | 20160831 | EXP | JP-JNJFOC-20160614755 | JANSSEN | TERAMURA Y, KAMEDA K, KANDA J, GOMYO A, HAYAKAWA J, AKAHOSHI Y, ET AL. DEVELOPMENT TUBERCULOUS MENINGITIS DURING CHEMOTHERAPY FOR CD5-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA. RINSHO KETSUEKI - JAPANESE JOURNAL OF CLINICAL HEMATOLOGY 2016;57 (5):597-601. | 62.00 | YR | A | F | Y | 0.00000 | 20160831 | OT | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124920223 | 12492022 | 1 | PS | DOXORUBICIN | DOXORUBICIN | 1 | Intravenous (not otherwise specified) | RCHOP REGIMEN | N | 50718 | LIPOSOME INJECTION | ||||||||
| 124920223 | 12492022 | 2 | SS | DOXORUBICIN | DOXORUBICIN | 1 | Unknown | RCHOP REGIMEN | U | 0 | UNSPECIFIED | ||||||||
| 124920223 | 12492022 | 3 | SS | CYCLOPHOSPHAMIDE. | CYCLOPHOSPHAMIDE | 1 | Unknown | RCHOP REGIMEN | U | 0 | UNSPECIFIED | ||||||||
| 124920223 | 12492022 | 4 | SS | VINCRISTINE | VINCRISTINE | 1 | Unknown | R-MPV ON DAY 12 | U | 0 | UNSPECIFIED | ||||||||
| 124920223 | 12492022 | 5 | SS | VINCRISTINE | VINCRISTINE | 1 | Unknown | RCHOP REGIMEN | U | 0 | UNSPECIFIED | ||||||||
| 124920223 | 12492022 | 6 | SS | PREDNISOLONE. | PREDNISOLONE | 1 | Unknown | R-MPV ON DAY 12 | U | 0 | UNSPECIFIED | ||||||||
| 124920223 | 12492022 | 7 | SS | METHOTREXATE. | METHOTREXATE | 1 | Unknown | U | 0 | UNSPECIFIED | |||||||||
| 124920223 | 12492022 | 8 | SS | METHOTREXATE. | METHOTREXATE | 1 | Unknown | R-MPV ON DAY 12 | U | 0 | UNSPECIFIED | ||||||||
| 124920223 | 12492022 | 9 | SS | DEXAMETHASONE. | DEXAMETHASONE | 1 | Unknown | U | 0 | UNSPECIFIED | |||||||||
| 124920223 | 12492022 | 10 | SS | PROCARBAZINE | PROCARBAZINE | 1 | Unknown | R-MPV ON DAY 12 | U | 0 | UNSPECIFIED | ||||||||
| 124920223 | 12492022 | 11 | SS | RITUXIMAB | RITUXIMAB | 1 | Unknown | ON DAY 12 | U | 0 | UNSPECIFIED | ||||||||
| 124920223 | 12492022 | 12 | SS | RITUXIMAB | RITUXIMAB | 1 | Unknown | RCHOP REGIMEN | U | 0 | UNSPECIFIED |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 124920223 | 12492022 | 1 | Diffuse large B-cell lymphoma |
| 124920223 | 12492022 | 2 | Diffuse large B-cell lymphoma |
| 124920223 | 12492022 | 3 | Diffuse large B-cell lymphoma |
| 124920223 | 12492022 | 4 | Diffuse large B-cell lymphoma |
| 124920223 | 12492022 | 5 | Diffuse large B-cell lymphoma |
| 124920223 | 12492022 | 6 | Diffuse large B-cell lymphoma |
| 124920223 | 12492022 | 7 | Diffuse large B-cell lymphoma |
| 124920223 | 12492022 | 8 | Diffuse large B-cell lymphoma |
| 124920223 | 12492022 | 9 | Diffuse large B-cell lymphoma |
| 124920223 | 12492022 | 10 | Diffuse large B-cell lymphoma |
| 124920223 | 12492022 | 11 | Diffuse large B-cell lymphoma |
| 124920223 | 12492022 | 12 | Diffuse large B-cell lymphoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 124920223 | 12492022 | HO |
| 124920223 | 12492022 | DE |
| 124920223 | 12492022 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 124920223 | 12492022 | Meningitis tuberculous | |
| 124920223 | 12492022 | Off label use | |
| 124920223 | 12492022 | Product use issue |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |